Summary
Prion diseases include Creutzfeldt-Jakob disease in humans, scrapie in sheep and bovine spongiform encephalopathy. The hallmark of prion diseases is the accumulation of an abnormal isoform (PrPSc) of the cellular prion protein accompanied by neuronal cell death and astroglial proliferation. To characterize the correlation between PrP secondary and quarternary structure and their biological effects we assayed soluble and aggregated forms of PrP 27–30, the N-terminal truncated form of PrPSc, as well as the corresponding recombinant PrP(90–231) for their neurotoxicity and infectivity. PrP was kept soluble in 0.2% SDS and subsequently reaggregated either by diluting the SDS or by adding acetonitril. The neurotoxicity of the re-aggregated states were comparable to that of prion rods (PrP 27–30) whereas the soluble forms had no neurotoxic effects. The solubilized PrP 27–30 showed no significant infection upon re-aggregation as determined by bioassays in Syrian golden hamsters. The recombinant PrP did not exhibit infectivity in any state.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Brown DR (2000) Neuronal release of vasoactive intestinal peptide is important to astrocytic protection of neurons from glutamate toxicity. Mol Cell Neurosci 15: 465–475
Brown DR, Pitschke M, Riesner D, Kretzschmar H (1998) Cellular effects of a neurotoxic prion protein peptide are related to its ß-sheet content. Neurosci Res Commun 23: 119–128
Brown DR, Qin K, Herms JW, Madlung A, Manson J, Strome R, Fraser PE, Kruck T, von-Bohlen A, Schulz-Schaeffer W, Giese A, Westaway D, Kretzschmar H (1997) The cellular prion protein binds copper in vivo. Nature 39: 684–687
Brown DR, Schmidt B, Kretzschmar HA (1996) A neurotoxic prion protein fragment enhances proliferation of microglia but not astrocytes in culture. Glia 18: 59–67
Brown DR, Schmidt B, Kretzschmar HA (1996) Role of microglia and host prion protein in neurotoxicity of prion protein fragment. Nature 380: 345–347
Forloni G, Angretti N, Chiesa R, Monzani E, Samona M, Bugiani O, Tagliavini F (1993) Neurotoxicity of a prion protein fragment. Nature 362: 543–546
Forloni G, Tagliavini F, Bugiani O, Salmona M (1996) Amyloid in Alzheimer’s disease and prion-related encephalopathies: studies with synthetic peptides. Progr Neurobiol 49: 287–315
Giese A, Brown DR, Groschup MH, Feldmann C, Haist I, Kretzschmar HA (1998) Role of microglia in neuronal cell death in prion disease. Brain Pathol 8: 449–457
Hill AF, Antoniou M, Collinge J (1999) Protease-resistant prion protein in vitro lacks detectable infectivity. J Gen Virol 80: 11–14
Kaneko K, Peretz D, Pan K-M, Blochberger TC, Wille H, Gabizon R, Griffith OH, Cohen F, Balwin MA, Prusiner SB (1995) Prion protein (PrP) synthetic peptide induce cellular PrP to acquire properties of the scrapie isoform. Proc Natl Acad Aci USA 92: 11160–11164
Kaneko K, Wille H, Mehlhorn I, Zhang H, Ball H, Cohen FE, Baldwin MA, Prusiner SB (1997a) Molecular properties of complexes formed between the prion protein and synthetic peptides. J Mol Biol 270: 547–586
Kocisko DA, Come JH, Priola SA, Chesebro B, Raymond GJ, Lansbury PT, Caughey B (1994) Cell-free formation of protease-resistant prion protein. Nature 370: 471–474
Mehlhorn I, Groth D, Stöckel J, Moffat B, Reilly D, Yansuro D, Willet WS, Baldwin M, Fletterick R, Cohen FE, Vandlen R, Henner D, Prusiner SB (1996) High-level expression and characterisation of a purified 142-residue polypeptide of the prion protein. Biochemistry 35: 5528–5537
Post K, Pitschke M, Schäfer O, Wille H, Appel TR, Kirsch D, Mehlhorn I, Serban H, Prusiner SB, Riesner D (1998) Rapid acquisition of ß-sheet structure in the prion protein prior to multimer formation. J Biol Chem 379: 1307–1317
Prusiner SB (1991) Molecular biology of prion diseases. Science 252: 1515–1522
Prusiner SB, Cochran SP, Groth DF, Downey DE, Bowman KA, Martinez HM (1982) Measurement of the scrapie agent using an incubation time interval assay. Ann Neurol 11: 353–358
Prusiner SB, Mc Kinley MP, Bowman KA, Bolton DC, Bendheim PE, Grothe DF, Glenner GG (1983) Scrapie prions aggregate to form amyloid-like birefringent rods. Cell 35: 349–358
Riesner D, Kellings K, Post K, Wille H, Serban H, Groth D, Baldwin MB, Prusiner SB (1996) Disruption of prion rods generate 10-nm spherical particles having high α-helical content and lacking scrapie infectivity. J Virol 70: 1714–1722
Stege GJJ, Renkawek K, Overkamp PSG, Verschuure P, van Rijk AF, Reijnen-Aalbers A, Boelens WC, Bosman GJGM, DeJong WW (1999) The molecular chaperone α-crystallin enhances amyloid ß neurotoxicity. Biochem Biophys Res Commun 262: 152–156
Walsh DM, Hartley DM, Kusumoto Y, Fezoui Y, Condron MM, Lomakin A, Bendek GB, Selkoe DJ, Teplow DB (1999) Amyloid ß-protein fibrillogenesis. J Biol Chem 274: 25945–25952
Wille H, Zhang G-F, Baldwin MA, Cohen FE, Prusiner SB (1996) Separation of scrapie prion infectivity from PrP amyloid polymers. J Mol Biol 259: 608–621
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2000 Springer-Verlag Wien
About this chapter
Cite this chapter
Post, K., Brown, D.R., Groschup, M., Kretzschmar, H.A., Riesner, D. (2000). Neurotoxicity but not infectivity of prion proteins can be induced reversibly in vitro. In: Groschup, M.H., Kretzschmar, H.A. (eds) Prion Diseases. Archives of Virology. Supplementa, vol 16. Springer, Vienna. https://doi.org/10.1007/978-3-7091-6308-5_25
Download citation
DOI: https://doi.org/10.1007/978-3-7091-6308-5_25
Publisher Name: Springer, Vienna
Print ISBN: 978-3-211-83529-6
Online ISBN: 978-3-7091-6308-5
eBook Packages: Springer Book Archive